IL6 and COVID-19: Though medium dose dexamethasone, IL6 antagonist such as tocilizumab, JAK kinase inhibitor such as baricitinib are recommended to reduce the inflammatory damage for severe COVID-19, their broad spectrum of immunosuppression also predispose patients to other infections31.